Cardiothoracic & vascular anesthesia

Opioid-Free Versus Opioid-Based Anesthesia on Postoperative Pain After Thoracoscopic Surgery: The Use of Intravenous and Epidural Esketamine

Anesth AnalgPublished Randomised controlled trial

Primary result · Mild chronic postoperative painResult — go to the resultOdds ratio 3.52 95% CI 1.49–8.31

Authors' conclusion

Replacement of opioids by esketamine, intraoperatively as intravenous injection and epidural infusion and postoperatively as epidural infusion, reduces the incidence of mild chronic postoperative pain and side effects in patients after VATS.

Study context

Population
Lung tumour patients scheduled for video-assisted thoracoscopic surgery (VATS)159 analysed
Participants
162 patients
Comparison
Opioid-free anaesthesia vs opioid-based anaesthesia
  • OAn = 79reference
  • Opioid-free anesthesia (OFA)n = 80
Primary endpoint
Chronic pain rate (logistic regression)
Follow-up
3 months after VATS
Methodological details2-centre, September 2021 to January 2022
  • 2-centre
  • September 2021 to January 2022

Primary result

Mild chronic postoperative pain · 3 months

Odds ratio

3.52

95% CI 1.49–8.31

P = 0.004

Events by treatment group

OA vs OFA
OR 3.52 (95% CI 1.49–8.31); P = 0.004

As reported in the abstract

Secondary outcomes

OutcomeOAOFAOR (95% CI)P value
Mild chronic pain · 6 months29.1%11.3%5.55 (2.01–15.33)P = 0.001
Acute postoperative pain · 24 hours0%17.5%52.14 (6.47–420.10)P < 0.001
Acute postoperative pain · 48 hours3.8%2.5%2.07 (0.99–4.32)P = 0.053

Safety

Side effects (nausea, vomiting, pruritus) · 48 hours after surgery

Fewer patients with side effects in the OFA group

Original publication

Opioid-Free Versus Opioid-Based Anesthesia on Postoperative Pain After Thoracoscopic Surgery: The Use of Intravenous and Epidural Esketamine. Anesth Analg. Published 14 July 2023. doi:10.1213/ane.0000000000006547

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.